Healthcare

AstraZeneca-Oracle partnership brings AI-enabled research to Abu Dhabi

A reported AstraZeneca-Oracle initiative will combine real-world data and AI for clinical research, beginning with hypertension work in Abu Dhabi.

The search results identify a global AstraZeneca-Oracle collaboration that includes projects in the Middle East, Europe, and the United States, with the first initiative planned for Abu Dhabi through M42. The partnership combines AstraZeneca’s drug-development and regulatory capabilities with Oracle’s real-world data, cloud infrastructure, and AI-enabled clinical tools. Its stated goals include improving clinical-trial recruitment, supporting earlier diagnosis, monitoring drug safety, and expanding use of real-world evidence. Within the GCC, Abu Dhabi is the named implementation site and hypertension is the first target. The project aims to help care teams find patients with uncontrolled hypertension, support treatment aligned with clinical guidelines, and streamline recruitment into research studies. These activities reflect practical AI applications rather than a purely technical research project. The source does not provide evidence that the system has already improved diagnosis, treatment, or trial enrollment. It describes an announced collaboration and planned program, so implementation status and measurable impact remain to be established. No additional GCC-specific articles were available in the supplied search results.

Original source: Ground News

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI